HOME > TOP STORIES
TOP STORIES
-
REGULATORY Panel on Generic Industry to Boot Up July 31, Report Expected by Fall
July 25, 2023
-
BUSINESS 7 Drugs Hit 100 Billion Yen Mark in FY2022 Japan Sales, Largest Number in 17 Years
July 24, 2023
-
BUSINESS Sosei to Acquire Idorsia’s Japan and Korea Arms for 65 Billion Yen
July 21, 2023
-
ORGANIZATION JPMA Says IRA Is “Alarming,” Set to Exchange Views with PhRMA
July 21, 2023
-
ORGANIZATION Pseudonymised Data Should Fuel Orphan Drug Discovery, but Criteria and Overseas Usage Must Be Discussed: JPMA
July 21, 2023
-
BUSINESS Heavy Demand Triggers Shipment Curb for High-Dose Mounjaro Just 1 Month after Launch
July 20, 2023
-
BUSINESS Astellas Becomes 1st Japan Pharma to Sue US Govt over IRA
July 19, 2023
-
REGULATORY Japan’s 1st Stelara, G-Lasta Biosimilars Nearing Finish Line
July 18, 2023
-
BUSINESS Gilead Japan Building Sales Force to Prep for Full Oncology Entry: Chief
July 14, 2023
-
REGULATORY Chuikyo Split over Drug Lags and Losses, Rapid Introduction Evaluation System
July 13, 2023
-
BUSINESS Meiji to Develop Lineup Unaffected by Price Revisions, Bolster Earnings from New Drugs/Generics in Focus Areas
July 12, 2023
-
REGULATORY MHLW Pharma Regulation Panel Kicks Off, Agrees to Discuss Incentives to Develop Pediatric Drugs
July 11, 2023
-
BUSINESS Shionogi to Cut 200 Jobs via Voluntary Buyout Program
July 11, 2023
-
ORGANIZATION Stop Requiring Japanese PI Data for Global Products: JPMA Officials
July 10, 2023
-
REGULATORY PMDA US Office to Set Out Solution for Drug Lag, Loss: Agency Chief
July 10, 2023
-
BUSINESS Full US Nod in Hand, Eisai CEO Keeps 1 Trillion Yen Sales Target for FY2030
July 10, 2023
-
BUSINESS FDA Awards Full Approval to Eisai’s Alzheimer’s Drug
July 7, 2023
-
REGULATORY Pharma Groups Float New Methods to Evaluate Innovative Drugs for 2024 Reform
July 6, 2023
-
REGULATORY Japan, US, Europe Trade Groups Urge Japan to Abolish “Spillover” Re-Pricing
July 6, 2023
-
BUSINESS Insmed Japan to Capitalize on Arikayce, Pins Hopes on Brensocatib: New President
July 5, 2023
ページ
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
